New Palexia® study confirms effective pain relief in long-term use
Chronic pain patients benefit from long-term tapentadol treatment
Aachen (ots)
- EMBARGO: This information is for healthcare professionals only.
Not intended for UK audience.
-A recent study published in the medical journal "Current Medical Research and Opinion"* has results that are good news for chronic pain patients.
This new trial was designed to meet real-life conditions in the treatment of severe chronic pain and included also a group with 588 chronic pain patients that were treated over 12 month. By using tapentadol prolonged release (PR) (Palexia®), more than half of these patients experienced a major reduction of pain intensity (by at least 50%). The proportion of patients with pain-free intervals rose from about 8 to 24% and the number of patients with uninterrupted sleep rose from approximately 9 to 35%.
At end of the observation, about 89% of patients had reached or exceeded their individual treatment target. The author, a pain specialist, concluded that tapentadol therapy provides stable pain relief for at least one year. The high efficiency and good tolerability confirm that tapentadol PR is a valuable alternative to classical strong opioids for the long-term management of chronic pain.
You can access the publication for free at http://informahealthcare.com/doi/full/10.1185/03007995.2014.939166
*Strick et al. 2014 Current Medical Research & Opinion posted online on July 15, 2014. (doi:10.1185/03007995.2014.939166)
About Grünenthal
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of E901 mn.
More information: www.grunenthal.com
Contact:
Jeanette Hübsch, Head of Brand Communication Palexia,
Grünenthal Europe & Australia,
Phone: +49 241-569-1487, email: jeanette.huebsch@grunenthal.com